Insider Buying: NextCure (NASDAQ:NXTC) Major Shareholder Purchases 36,303 Shares

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc bought 36,303 shares of the firm’s stock in a transaction on Friday, July 31st. The shares were bought at an average cost of $4.94 per share, with a total value of $179,336.82. Following the transaction, the insider directly owned 722,419 shares of the company’s stock, valued at approximately $3,568,749.86. This trade represents a 5.29% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Thursday, July 30th, Adar1 Capital Management, Llc purchased 292,850 shares of NextCure stock. The shares were bought at an average price of $4.93 per share, for a total transaction of $1,443,750.50.
• On Wednesday, July 29th, Adar1 Capital Management, Llc purchased 3,410 shares of NextCure stock. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $17,050.00.
• On Tuesday, July 28th, Adar1 Capital Management, Llc purchased 6,400 shares of NextCure stock. The stock was purchased at an average cost of $4.95 per share, for a total transaction of $31,680.00.
• On Monday, July 27th, Adar1 Capital Management, Llc acquired 7,798 shares of NextCure stock. The stock was purchased at an average price of $5.00 per share, with a total value of $38,990.00.

NextCure Price Performance

Shares of NASDAQ NXTC traded up $0.26 during trading hours on Monday, hitting $4.40. 405,433 shares of the stock were exchanged, compared to its average volume of 931,919. NextCure, Inc. has a one year low of $1.55 and a one year high of $15.74. The company’s 50 day moving average is $3.49 and its 200 day moving average is $8.65. The firm has a market capitalization of $15.89 million, a P/E ratio of -0.26 and a beta of 1.42.

NextCure (NASDAQ:NXTC) last announced its earnings results on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, topping the consensus estimate of ($2.10) by $0.23. Research analysts anticipate that NextCure, Inc. will post -7.89 earnings per share for the current fiscal year.

Institutional Trading of NextCure

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in shares of NextCure by 18.6% during the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after purchasing an additional 3,636 shares during the period. Renaissance Technologies LLC raised its position in shares of NextCure by 18.7% during the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after buying an additional 5,300 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of NextCure in the fourth quarter valued at about $160,000. Millennium Management LLC bought a new stake in shares of NextCure in the fourth quarter valued at about $185,000. Finally, Affinity Asset Advisors LLC lifted its stake in shares of NextCure by 28.9% in the fourth quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock valued at $3,509,000 after buying an additional 55,412 shares during the period. 42.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NXTC has been the subject of several research analyst reports. Zacks Research raised NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of NextCure in a report on Wednesday, July 15th. Wall Street Zen downgraded NextCure from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, Weiss Ratings lowered NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $19.00.

NextCure Company Profile

NextCure, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large?scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.